131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
about
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelRadioimmunotherapy of human tumoursAllogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.Conditioning regimens for hematopoietic cell transplantation: one size does not fit allSignificance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.Pretargeted radioimmunotherapy for hematologic and other malignanciesAnti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maAllogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.Pharmacodynamic study of (131)I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer.Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftmentSimultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenograftsRituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromesStrategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.Radioimmunotherapy-based conditioning regimens for stem cell transplantationBiodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.Cancer stem cells: relevance to SCTNon-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin.Antibody-based therapy of leukaemia.Optimising the conditioning regimen for acute myeloid leukaemia.Construction and expression of a human/mouse chimeric CD19 monoclonal antibody: Successful modification of a murine IgM to a chimeric IgG.Advances in the treatment of hematologic malignancies using immunoconjugatesThe clinical and therapeutic implications of cancer stem cell biology.The road to purified hematopoietic stem cell transplants is paved with antibodies.Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome.Radioimmunotherapy for hematopoietic cell transplantation.Antibody therapy for acute myeloid leukaemia.
P2860
Q24629826-50729872-EFD8-4EA0-B484-C9C6FBF0238FQ28088825-ACA627D8-A88D-4247-A008-BDEA8C5FEFC7Q30399209-60EA891A-69AE-41D8-AC74-62199CA7A27EQ33388983-3ACAE731-230E-4F4B-8CD4-05B4EB8DF196Q33560410-749B1BC1-5306-4819-A727-6200CC8C38E9Q33886217-F250B368-2F0F-4D15-9641-06AD5E0927A3Q33917170-1428C28C-05B2-4073-9077-403BA8654EB1Q33931553-5EEC9F36-86A8-4051-8E1A-8A1D11C180B5Q34022682-E2A53F4C-5C86-45EF-9FB9-601602C301D7Q34113941-42FBF468-0C9F-4DD8-958B-0C955D90E8D7Q34612119-C2ADAB88-3828-44B3-A06E-5513ABE3A4DAQ35605318-0DFDCDE1-4303-43BA-ADAD-19115831279FQ35640788-BB7D711D-C851-43E9-A405-79346AE7041BQ35808597-3347FD36-2C17-4142-8D74-9C6DBB4A52ECQ35870549-749620C1-382C-4DFD-9E49-1650365FFD8BQ36445890-9BA3C69D-2706-43EF-B735-C7B31CA4AA2BQ36488985-B9D4D256-1043-4852-BF3C-A90078E4E563Q36591404-D40F5F73-DEC2-4FAC-9CF4-07522076240DQ36787584-91E9C36C-EC6F-4174-9801-DE1F4288098EQ36814661-5B3A43A1-2BC3-4C43-9CD0-50D016F20389Q36984304-86B3F64B-15C1-49AB-AEC2-ED34FB30CB3CQ37000485-B393E30E-B21F-4E9E-BB35-45A5810F9E93Q37036289-7EA2E844-DC6C-4DEA-9942-48A2E30F13C6Q37125119-CE77C9B8-68AE-4E9C-9A5D-EB0DD26795C7Q37133715-59E072FD-7453-4956-986B-15D86BAE2C2FQ37159533-5D718C6D-978E-4482-B231-E3CEF13A0125Q37174938-CAAFF9D6-82C7-4553-BAB7-6574E1542718Q37237469-6FDEA539-67C9-4BD0-B31C-12C972BD9C2DQ37295150-073A2391-31D3-44C8-BD7F-109BC40FF901Q37398584-0DCAC713-46A6-43F7-BADE-21F49DE138A2Q37527541-BD79A194-2FB3-46F9-9D9F-235D58872FDBQ37605247-C1EEEC95-1363-4574-9395-B0A863802C83Q37644054-09FB3EF1-073B-4AFA-A0F0-03DD96D32010Q37652075-83529E20-28CA-4B2D-AC41-FBE785300F67Q37697843-E8A57212-AD63-4FC8-ACAF-1FC0DBF7ED40Q37909375-391E8DC5-831F-49C9-8AD5-5CA46E433D84Q38039703-499FCD36-9E37-4553-993D-6E4674982106Q38095962-F6DEAD22-00EC-42A5-ACBE-F8D2D104A876Q38096058-2581EF49-39A2-4A29-B500-9DA3FC3823C0Q38169814-836FAB1E-79DA-4FC6-AACA-B3BF6A108F0F
P2860
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
131I-anti-CD45 antibody plus b ...... d leukemia in first remission.
@ast
131I-anti-CD45 antibody plus b ...... d leukemia in first remission.
@en
type
label
131I-anti-CD45 antibody plus b ...... d leukemia in first remission.
@ast
131I-anti-CD45 antibody plus b ...... d leukemia in first remission.
@en
prefLabel
131I-anti-CD45 antibody plus b ...... d leukemia in first remission.
@ast
131I-anti-CD45 antibody plus b ...... d leukemia in first remission.
@en
P2093
P2860
P1433
P1476
131I-anti-CD45 antibody plus b ...... id leukemia in first remission
@en
P2093
Dana C Matthews
Darrell R Fisher
Eileen Sickle
Eneida Nemecek
Frederick R Appelbaum
Irwin D Bernstein
Janet F Eary
Jeanette Carreras
John M Pagel
Joseph Rajendran
P2860
P304
P356
10.1182/BLOOD-2005-06-2317
P407
P577
2005-10-27T00:00:00Z